44 countries have announced the varieties of medical insurance negotiations. 1 Where is it missing?

Medical Cloud Studio: Digging the Value in the Trend

Text: Diancanghe

The negotiation list was announced today, with 44 varieties.

Today, Ministry of Human Resources and Social Security announced that 44 varieties have been included in the national medical insurance negotiations. The list of medicines is as follows:

20 17 negotiation scope of national drug list of basic medical insurance, industrial injury insurance and maternity insurance

Serial number drug name manufacturing enterprise

1 Ginkgolide Injection Chengdu White

2 Xinmailong injection Yunnan rattan medicine

3 Shenyi Capsule Jilin Yatai

Astragalus polysaccharide for injection Tianjin Sino

5 Xuebijing Injection Hongri Pharmaceutical

6 Compound Huangdai Tablet Yifan Pharmaceutical Industry

7 Injection of Yiqi Fumai (freeze-dried) Tasly

8 Ginkgo Diterpenoid Glucosamine Injection Kangyuan Pharmaceutical

9 Alisartan Ester Tablets Xinlitai

10 qidamin tablet micro-core organism

1 1 morpholinonidazole sodium chloride injection Jiangsu Haosen

12 Kangbai Xipu Ophthalmic Injection Kanghong Pharmaceutical

13 recombinant human endostatin injection

14 apatinib mesylate tablets hengrui pharmaceutical

15 paclitaxel liposome green leaf pharmaceutical for injection

16 recombinant human prourokinase for injection

17 Yuri klinputian pharmaceutical co., ltd. for injection

18 recombinant human brain natriuretic peptide for injection Chengdu nuodikang

19 cyfluthrin injection AstraZeneca

AstraZeneca 20 Quetiapine Sustained-release Tablets

2 1 tegolol tablets AstraZeneca

22 Bosentan tablets Actelion

23. nimotuzumab Injection Baitai Bio

Sorafenib Toluene Sulfonate Tablets Bayer

25 recombinant human interferon β- 1b layer for injection

Rapatinib 26 Toluene Sulfonic Acid Tablets GSK

Paroxetine hydrochloride enteric-coated sustained-release tablets

28 Carbonate Division Villam Tablets Sanofi

29 Bevacizumab Injection Roche

30 erlotinib hydrochloride tablets Roche

3 1 Rocili Toximab Injection

32 Tratuzumab Roche for Injection

33 Cetuximab Injection Merck

34 liraglutide injection novonordisk

35 recombinant human coagulation factor ⅶ A Novo Nordisk for injection

36 Novartis injection

Novartis everolimus tablets

38 lanthanum carbonate chewable tablets Xiaer Pharmaceutical

39 Lenalidomide Capsules Xinji Pharmacy

40 Abiraterone Acetate Tablets Janssen

4 1 bortezomijanssen for injection

Infliximab for injection (Crohn's disease only) Janssen

43 Torvalptan Tablets Otsuka Pharmaceutical

posaconazole oral suspension

Foreign pharmaceutical companies entered 26 varieties, accounting for 59%, and ginkgolides all entered.

Judging from the varieties of the above-mentioned negotiation list, both domestic-funded enterprises and foreign-funded pharmaceutical companies are shortlisted, and Chinese patent medicines for biochemical drugs are also sideways. However, 26 varieties of foreign-funded pharmaceutical companies entered the negotiation list, accounting for 59%.

Judging from the number of negotiation varieties selected by manufacturers, foreign-funded enterprises are also conspicuous, including:

Roche: 4

AstraZeneca: 3 people

Yang Sen: Three.

Bayer, GlaxoSmithKline, Novartis and Novo Nordisk each have two.

However, only Tasly has two finalists among domestic enterprises.

In addition, it is worth mentioning that White Ginkgolide Injection and Kangyuan Ginkgolide Glucosamine Injection were also included in the negotiation list.

These two varieties have been sought after by the market since they were approved for listing around 20 10. However, due to the high pricing, extremely high agency conditions, and the influence of bidding and medical insurance, the market situation has not been able to meet the company's initial expectations. This time, both competing products have been selected for the negotiation, and one foot has entered the door of medical insurance, but whether it can be negotiated into a good price depends on their own nature.

The result of entering the negotiation list will be: price reduction, substantial price reduction! , but the sales volume may be very large.

At the national level, the National Health Planning Commission negotiated three kinds of drugs on 20 15 1 1, and the price was reduced by more than half:

Tenofovir disoproxil fumarate fumarate (GSK) decreased by 67%.

AstraZeneca Iressa, down 54%

Zhejiang Peking University Kemena, down 55%

After GSK changed its drug marketing model in China, medical representatives no longer took sales as the assessment target, which once caused controversy. After tenofovir reduced its price by 67% through national negotiations, the industry was worried about GSK's performance. However, according to Ji, the person in charge of GSK, the sales volume of tenofovir disoproxil fumarate fumarate increased by three times in the whole country, and by four to five times in the cities where the negotiated prices landed.

As a representative of domestic drugs, what changes have taken place in the market sales of KeMyna after the price reduction?

The 20 16 annual report just released by Zhejiang Beida Pharmaceutical Co., Ltd. shows that in 20 16, Kamena's sales exceeded 10 billion, up by 3 1.46% year-on-year, up by 13.36% year-on-year, mainly due to 20/kloc.

Due to the lag of market reaction, after the price reduction of 54%, the sales increment is still released, and the growth rate of sales revenue is lower than that of sales. After Comena is newly included in the 20 17 medical insurance catalogue, the breakthrough of market access will be beneficial to the sales of the company's products.

Therefore, after the previous negotiated varieties entered the medical insurance at a reduced price, the sales volume increased. It seems that the negotiated varieties of national medical insurance can also be increased through the promotion of medical insurance reimbursement. However, market competition not only solves the access problem, but everything will be fine. Whether it can really bring returns through medical insurance benefits depends on the subsequent market and sales volume.

Why are there only 44 varieties negotiated and 45 agreed? Where is one of them?

At the press conference during the two sessions this year, a reporter asked, last year, the National Health and Family Planning Commission initiated the first round of drug price negotiations, and this year, 45 drugs were selected for negotiation. How much does the National Health and Family Planning Commission intend to reduce the price?

Li Bin said that national negotiation is an effective way to reduce drug prices, but it is not the only way. This year, the human and social departments and the health and family planning departments have selected a number of varieties that may be subject to price negotiations according to clinical needs. At present, this work has not been finalized. After confirmation, the information will be made public.

Li Bin said that he is open to enterprises that produce this drug. The general principles are as follows: First, it is urgently needed in clinic. Second, practice has proved that this effect is better. Third, choose from this kind of drug with relatively high price and heavy burden on the masses.

Then the problem is coming. What about the 45 negotiating varieties? Why have only 44 books been published? Who hasn't announced it yet? Will it be included in the negotiations?

In this regard, the answer was actually found on the day when the 20 17 version of the medical insurance catalogue was published. Ministry of Human Resources and Social Security once said that 45 drugs to be negotiated were identified by experts at the same time, all of which are patents and exclusive drugs with high clinical value but relatively expensive price. In the next step, the list of drugs to be negotiated will be announced to the public, and negotiations will be organized according to relevant procedures after confirming whether the enterprise has the intention to negotiate.

The variety that didn't enter the negotiation was nelofloxacin malate capsules?

Therefore, Ministry of Human Resources and Social Security has drawn up a list of negotiations, but this does not mean that all enterprises are willing to participate in the negotiations. After all, there has been a precedent of halving the price of three varieties negotiated by the state. In the initial stage of market promotion, innovative drugs need to be widely exposed to clinic, and good price space is a necessary prerequisite for promotion. Therefore, relevant enterprises should make a comprehensive evaluation on whether to participate in the negotiations and accept the price reduction.

Market analysis researchers believe that the nano-ofloxacin malate capsule (Xinchang Pharmaceutical Factory of Zhejiang Pharmaceutical Co., Ltd.) approved on 20 16 should be a "missing" variety that has not entered the 45 negotiation catalogues.

Nelofloxacin malate is a new fluoroquinolone-free drug, which has two dosage forms, oral and injection, and is not easy to produce drug-resistant strains. It can be used as the first-line drug for community-acquired pneumonia and has the extension of other indications.

It is understood that in 20 15 years, the global sales of quinolones similar to nelofloxacin malate was $2.023 billion, and the sales of drugs in important city hospitals in the domestic market were/kloc-0.559 billion yuan.

At present, there are moxifloxacin and levofloxacin in the domestic market, and the main manufacturers are Bayer, First Pharmaceutical (Beijing) Co., Ltd., Jiangsu Yang Zijiang Pharmaceutical Group Company and Zhejiang Pharmaceutical Xinchang Pharmaceutical Factory.

Among them, levofloxacin lactate (trade name "Lailixin"), a quinolone product of Zhejiang Medicine Xinchang Pharmaceutical Factory, is the company's leading product, with annual sales of 326 million yuan in 20 15. The successful listing of nelofloxacin malate capsules will further enrich the company's product categories.

Boldly explore the way of market access

On February 23rd, Ministry of Human Resources and Social Security announced the publication of the 20 17 medical insurance catalogue, which included 2,535 western medicines and Chinese medicines, an increase of 339 compared with the 2009 edition, with an increase of about 15.4%. However, in a sense, the catalogue cannot be regarded as a "complete version" because there are still some special varieties that need to be negotiated to complete the final medical insurance access.

For exclusive, patented and overburdened varieties, national negotiation can encourage innovation on the one hand and reduce the economic burden of patients' medication on the other. It can be predicted that with the continuous introduction of innovative drugs, the market access mode will be adjusted according to the actual situation of social, economic and medical development. The exploration of national negotiation as an access mode is not over yet, and we are happy to see it come true.